Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 283

1.

Thyroid disorders in Programmed Death-1 inhibitors treated patients: is previous therapy with Tyrosine Kinase Inhibitors a predisposing factor?

Sbardella E, Tenuta M, Sirgiovanni G, Gianfrilli D, Pozza C, Venneri MA, Cortesi E, Marchetti P, Lenzi A, Gelibter AJ, Isidori AM.

Clin Endocrinol (Oxf). 2019 Dec 1. doi: 10.1111/cen.14135. [Epub ahead of print]

PMID:
31788837
2.

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios.

Pizzuti L, Krasniqi E, Barchiesi G, Mazzotta M, Barba M, Amodio A, Massimiani G, Pelle F, Kayal R, Vizza E, Grassadonia A, Tomao S, Venuti A, Gamucci T, Marchetti P, Natoli C, Sanguineti G, Ciliberto G, Vici P.

J Cancer. 2019 Oct 12;10(24):5903-5914. doi: 10.7150/jca.35109. eCollection 2019. Review.

3.

Insulin Resistance as a Risk Factor for Cutaneous Melanoma. A Case Control Study and Risk-Assessment Nomograms.

Scoppola A, Strigari L, Barnabei A, Petasecca P, De Galitiis F, Fulgenzi CAM, Roselli M, De Lorenzo A, Di Renzo L, Marchetti P, Torino F.

Front Endocrinol (Lausanne). 2019 Nov 5;10:757. doi: 10.3389/fendo.2019.00757. eCollection 2019.

4.

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.

Cortellini A, Vitale MG, De Galitiis F, Di Pietro FR, Berardi R, Torniai M, De Tursi M, Grassadonia A, Di Marino P, Santini D, Zeppola T, Anesi C, Gelibter A, Occhipinti MA, Botticelli A, Marchetti P, Rastelli F, Pergolesi F, Tudini M, Silva RR, Mallardo D, Vanella V, Ficorella C, Porzio G, Ascierto PA.

J Transl Med. 2019 Nov 15;17(1):376. doi: 10.1186/s12967-019-02132-x.

5.

Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience.

Valeriani M, Marinelli L, Macrini S, Reverberi C, Aschelter AM, De Sanctis V, Marchetti P, Tronnolone L, Osti MF.

Radiat Oncol. 2019 Nov 14;14(1):205. doi: 10.1186/s13014-019-1414-x.

6.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.

Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.

Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.

7.

4th ESPT Conference: pharmacogenomics and personalized medicine - research progress and clinical implementation.

Sipeky C, Llerena A, Manolopoulos VG, Pearson E, Mlakar V, Gozzo L, Simmaco M, Marchetti P, Re MD, Stankovic S, Meyer U, Cascorbi I, Ingelman-Sundberg M, Suarez-Kurtz G, Marc J, Katsila T, Paulmichl M, Nofziger C, Ansari M, Drago F, van Schaik RH.

Pharmacogenomics. 2019 Oct;20(15):1063-1069. doi: 10.2217/pgs-2019-0095.

PMID:
31588876
8.

Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network.

Ciccarone M, Hohaus S, Pulsoni A, Cavaceppi P, Franzò S, Fabbri R, Cudillo L, Battistini R, Di Rocco A, Annibali O, Cox MC, Provenzano I, Abruzzese E, Renzi D, Tesei C, Anticoli Borza P, Cuccaro A, Andriani A, D'Elia GM, Facchiano A, Marchetti P, Cantonetti M.

Eur J Cancer Care (Engl). 2019 Sep 30:e13174. doi: 10.1111/ecc.13174. [Epub ahead of print]

PMID:
31571303
9.

Response to: Comment on "Impact of tumor site on the prognosis of small bowel adenocarcinoma".

Falcone R, Strigari L, Farina L, Marchetti P.

Tumori. 2019 Sep 30:300891619878898. doi: 10.1177/0300891619878898. [Epub ahead of print] No abstract available.

PMID:
31570060
10.

Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment.

Ascierto PA, Borgognoni L, Botti G, Guida M, Marchetti P, Mocellin S, Muto P, Palmieri G, Patuzzo R, Quaglino P, Stanganelli I, Caracò C.

J Transl Med. 2019 Sep 18;17(1):315. doi: 10.1186/s12967-019-2067-0.

11.

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.

Facchini G, Rossetti S, Berretta M, Cavaliere C, Scagliarini S, Vitale MG, Ciccarese C, Di Lorenzo G, Palesandro E, Conteduca V, Basso U, Naglieri E, Farnesi A, Aieta M, Borsellino N, La Torre L, Iovane G, Bonomi L, Gasparro D, Ricevuto E, De Tursi M, De Vivo R, Lo Re G, Grillone F, Marchetti P, De Vita F, Scavelli C, Sini C, Pisconti S, Crispo A, Gebbia V, Maestri A, Galli L, De Giorgi U, Iacovelli R, Buonerba C, Cartenì G, D'Aniello C.

J Transl Med. 2019 Aug 29;17(1):296. doi: 10.1186/s12967-019-2047-4.

12.

Sometimes, the Least Demanding Solution Is the Most Suitable: A Careful Survey of NMR Spectra of a Phosphonium Salt Accounted for Its "Unusual Wittig Reaction".

Fantinati A, Marchetti P, Trapella C, Zanirato V.

ACS Omega. 2018 Jul 19;3(7):8091-8096. doi: 10.1021/acsomega.8b01228. eCollection 2018 Jul 31.

13.

Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.

Rossi A, Roberto M, Panebianco M, Botticelli A, Mazzuca F, Marchetti P.

Eur J Pharmacol. 2019 Nov 5;862:172621. doi: 10.1016/j.ejphar.2019.172621. Epub 2019 Aug 22. Review.

14.

New paradigm for stage III melanoma: from surgery to adjuvant treatment.

Ascierto PA, Borgognoni L, Botti G, Guida M, Marchetti P, Mocellin S, Muto P, Palmieri G, Patuzzo R, Quaglino P, Stanganelli I, Caracò C.

J Transl Med. 2019 Aug 14;17(1):266. doi: 10.1186/s12967-019-2012-2. Review. Erratum in: J Transl Med. 2019 Sep 18;17(1):315.

15.

Clinical Impact of Highly Purified, Whey Proteins in Patients Affected With Colorectal Cancer Undergoing Chemotherapy: Preliminary Results of a Placebo-Controlled Study.

Mazzuca F, Roberto M, Arrivi G, Sarfati E, Schipilliti FM, Crimini E, Botticelli A, Di Girolamo M, Muscaritoli M, Marchetti P.

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419866920. doi: 10.1177/1534735419866920.

16.

Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases.

Cortinovis D, Chiari R, Catino A, Grossi F, DE Marinis F, Sperandi F, Piantedosi F, Vitali M, Parra HJS, Migliorino MR, Tondini C, Tassinari D, Frassoldati A, Verderame F, Pazzola A, Cognetti F, Palmiotti G, Marchetti P, Santoro A, Giannarelli D, Colonese F, Delmonte A.

Anticancer Res. 2019 Aug;39(8):4265-4271. doi: 10.21873/anticanres.13590.

PMID:
31366516
17.

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.

Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P.

Int J Cancer. 2019 Jul 22. doi: 10.1002/ijc.32583. [Epub ahead of print]

PMID:
31330065
18.

Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study.

Parisi A, Cortellini A, Roberto M, Venditti O, Santini D, Dell'Aquila E, Stellato M, Marchetti P, Occhipinti MA, Zoratto F, Mazzuca F, Tinari N, De Tursi M, Iezzi L, Natoli C, Ratti M, Pizzo C, Ghidini M, Porzio G, Ficorella C, Cannita K.

J Cancer Res Clin Oncol. 2019 Sep;145(9):2365-2373. doi: 10.1007/s00432-019-02971-7. Epub 2019 Jul 6.

PMID:
31280347
19.

Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer.

Annunziata MC, De Stefano A, Fabbrocini G, Leo S, Marchetti P, Romano MC, Romano I.

Clin Drug Investig. 2019 Sep;39(9):825-834. doi: 10.1007/s40261-019-00811-7. Review.

PMID:
31264159
20.

Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center.

Magi L, Mazzuca F, Rinzivillo M, Arrivi G, Pilozzi E, Prosperi D, Iannicelli E, Mercantini P, Rossi M, Pizzichini P, Laghi A, Signore A, Marchetti P, Annibale B, Panzuto F.

J Clin Med. 2019 Jun 25;8(6). pii: E910. doi: 10.3390/jcm8060910.

Supplemental Content

Loading ...
Support Center